Compare Equitable Holdings Inc. Common Stock (EQH) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs ResMed Inc. — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.42B), while ResMed Inc. trades at $236.34 (market cap $33.09B). The key difference: ResMed Inc. is far larger — about 2.3× Equitable Holdings Inc. Common Stock's market cap, and Equitable Holdings Inc. Common Stock pays the higher dividend (2.16%). Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and ResMed Inc. for 51 Days on average.
| EQH | RMD | |
|---|---|---|
Market Cap | $14.42B | $33.09B |
Volume | 2,107,298 | 1,019,685 |
Sector | Financials | Health |
52-Week High | $54.50 | $275.96 |
52-Week Low | $35.34 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $5.48B | $32.45B |
Dividend Yield | 2.16% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
ResMed (RMD) trades at $235.04, up 0.19% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $243.56. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding expectations. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%, while cash flow from operations reached $1.75B. Recent news highlights upcoming Q1 2027 earnings and a Morgan Stanley conference presentation focusing on growth targets.
The outlook for RMD is positive, driven by consistent earnings outperformance, high profitability, and institutional buying interest. Key opportunities include market share gains and product innovation in sleep therapy, though risks involve competitive pressures and ongoing legal investigations. The stock's current valuation metrics, including a P/E of 22.56, appear reasonable relative to growth, supporting a constructive view for investors seeking exposure to healthcare equipment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
